BioTuesdays

Tag - Joseph Pantginis

OmniAb Logo

HCW starts OmniAb at buy; PT $11

H.C. Wainwright launched coverage of OmniAb (NASDAQ:OABI) with a “buy” rating and a price target of $11. The stock closed at $3.88 on Feb. 10. At its core, OmniAb is an antibody discovery, optimization, and licensing...

Clene Logo

HCW starts Clene at buy; PT $16

H.C.Wainwright initiated coverage of Clene (NASDAQ:CLNN) with a “buy” rating and price target of $16. The stock closed at $4.50 on July 15. Clene is focused on the development of novel clean-surfaced nanotechnologies...

Shattuck Labs

HCW starts Shattuck Labs at buy; PT $28

H.C. Wainwright initiated coverage of Shattuck Labs (NASDAQ:STTK) with a “buy” rating and price target of $28. The stock closed at $3.84 on April 29. To overcome the shortcomings of current immunomodulatory cancer...

biophytis

HCW starts Biophytis at buy; PT $15

H.C. Wainwright initiated coverage of Biophytis SA of France (NASDAQ:BPTS) with a “buy” rating and $15 price target. The stock closed at $6.09 on Oct. 22. As a spin-off from Sorbonne University in 2006, Biophytis has...

Progenity-New

HCW starts Progenity at buy; PT $4

H.C. Wainwright launched coverage of Progenity (NASDAQ:PROG) with a “buy” rating and price target of $4. The stock closed at $2.04 on Oct. 13. Progenity’s differentiated R&D pipeline primarily focuses on employing...

BeyondSpring Logo

HCW ups BeyondSpring to buy from neutral; PT $100

H.C. Wainwright upgraded BeyondSpring (NASDAQ:BYSI) to “buy” from “neutral” with a price target of $100 after the company reported positive topline results from its DUBLIN-3 registrational trial of plinabulin in...

PDS Biotechnology Logo

HCW ups PDS Biotechnology PT to $20 from $8

H.C. Wainwright raised its price target for PDS Biotechnology (NASDAQ:PDSB) to $20 from $8 ahead of additional data being released at the ASCO meeting this weekend. The stock closed at $10.86 on June 1. “We believe that...